Hopital Cardiologique — Clinical Trial Site

13 Registered trials

3 Currently recruiting

Organisation

Hopital Cardiologique

Location

Lille Cedex, France

Identifier

ORG-100029387

Address

Boulevard Du Professeur Jules Leclercq, 59037, France

Departments

2307: Pulmonary - Thoracic Oncology
CARDIOLOGY
Centre d'investigation clinique (CIC) à l'Institut Coeur Poumon
CIC
N/A
Pneumologie
Pneumology
Pneumology and immuno Allergology
Pneumology and Thoracic Oncology
Pulmonology and Thoracic Oncology
Service de Pneumologie et Immuno-Allergologie

Clinical trials at this site (13)

Search interface

A Phase 3 Study of I-DXd in Subjects with Relapsed SCLC Recruiting

2023-509628-16-00 Small Cell Lung Cancer (SCLC) 5 2026-05-07
A trial to learn how safe Dato-DXd is and how well it works in people with NSCLC that has advanced after receiving osimertinib Recruiting

2024-511362-37-00 Non squamous non-small cell lung cancer (NSCLC) 5 2026-02-18
Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 o… Recruiting

2024-515658-26-00 Unresectable or Metastatic HER2 overexpressing and PD-L 5 2026-01-21
DAPAgliflozine to attenuate cardiac RemOdeling afTEr aCuTe myOcardial infarction Ended

2024-511882-13-01 Cardiac failure 5 2024-11-19
A research study looking at long-term treatment with Mim8 in people with haemophilia A (FRONTIER 4) Ended

2022-502215-10-00 Haemophilia A (with or without inhibitors) 5 2023-05-04
A Phase 3 Study of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Ended

2024-514173-22-00 Cystic Fibrosis 5 2023-02-28
Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor Long-term Safety and Efficacy in Subjects Without F508del Ended

2024-515637-14-00 Cystic Fibrosis 5 2022-11-08
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Ended

2023-507263-19-00 Advanced Non-Small Cell Lung Cancer 5 2020-12-23
Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Ended

2024-512554-15-00 COVID-19 5 2023-06-21
Symptoms control and adhErenCe assessment during treatment with mepolizUmab new pREfilled devices. SECURE Ended

2022-501029-19-00 Asthma 6 2022-12-13
Non-inferiority study of GSK3511294 (depemokimab) compared with mepolizumab or benralizumab in participants with severe asthma with an eosin… Ended

2023-510230-84-00 Severe asthma with an eosinophilic phenotype 5 2021-05-28
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended

2023-503673-38-00 Adults at high risk of cardiovascular events without pr 5 2019-05-24
Study of BMS-986466 with Adagrasib with or without Cetuximab in Participants with KRAS G12C-mutant Solid Tumors Ended

2023-505070-15-00 Oncology, NSCLC and CRC 9